Enliven Therapeutics Inc Com (NASDAQ: ELVN) stock closed at 23.49 per share at the end of the most recent trading day (a -17.01% change compared to the prior day closing price) with a volume of 2.15K shares and market capitalization of 810.08M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 0 people. Enliven Therapeutics Inc Com CEO is Sam Kintz.

The one-year performance of Enliven Therapeutics Inc Com stock is %, while year-to-date (YTD) performance is 20.48%. ELVN stock has a five-year performance of %. Its 52-week range is between 3.8956 and 25.34, which gives ELVN stock a 52-week price range ratio of %

Enliven Therapeutics Inc Com currently has a PE ratio of -, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -%, a ROC of -% and a ROE of -%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $- revenue per share.

Of the last four earnings reports from Enliven Therapeutics Inc Com, there were 2 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.81 for the next earnings report. Enliven Therapeutics Inc Com’s next earnings report date is 05th May 2023.

The consensus rating of Wall Street analysts for Enliven Therapeutics Inc Com is Moderate Buy (1.67), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Enliven Therapeutics Inc Com stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Enliven Therapeutics Inc Com has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Enliven Therapeutics Inc Com has a Buy technical analysis rating based on Technical Indicators (ADX : 20.03, ATR14 : 2.11, CCI20 : 37.06, Chaikin Money Flow : 0.40, MACD : 3.56, Money Flow Index : 53.01, ROC : -0.57, RSI : 49.25, STOCH (14,3) : 42.44, UO : 66.92, Williams %R : -57.56), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Enliven Therapeutics Inc Com in the last 12-months were: Michael P. Gray (Sold 3 596 shares of value $14 096 ), Rahul D. Ballal (Sold 11 313 shares of value $44 234 )